Biodexa Pharmaceuticals (BDRX) Total Liabilities (2013 - 2025)

Biodexa Pharmaceuticals (BDRX) has 13 years of Total Liabilities data on file, last reported at $9.0 million in Q4 2025.

• For the quarter ending Q4 2025, Total Liabilities rose 8.71% year-over-year to $9.0 million; the trailing twelve-month figure through Dec 2025 stood at $9.0 million (up 8.71% YoY), and the FY2025 full-year result was $8.9 million, up 7.75% from the prior year.
• Total Liabilities improved to $9.0 million in Q4 2025, from $4.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $9.0 million in Q4 2025 to a low of $2.8 million in Q2 2022.
• A 5-year average of $5.4 million and a median of $5.4 million in 2021 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities slumped 56.36% in 2022 and jumped 162.59% in 2023, its largest moves.
• Tracing BDRX's Total Liabilities over 5 years: stood at $3.3 million in 2021, then declined by 16.45% to $2.8 million in 2022, then jumped by 162.59% to $7.3 million in 2023, then rose by 13.89% to $8.3 million in 2024, then rose by 8.71% to $9.0 million in 2025.
• Business Quant data shows BDRX's Total Liabilities at $9.0 million in Q4 2025, $4.5 million in Q2 2025, and $8.3 million in Q4 2024.